Thiazolidinediones improve hepatic fibrosis in rats with non-alcoholic steatohepatitis by activating the adenosine monophosphate-activated protein kinase signalling pathway

Clinical and Experimental Pharmacology and Physiology

Volumn 39, Issue 12, 2012, Pages 1026-1033

  Zhang, Wei ^a   Wu, Rong ^a   Zhang, Feng ^a   Xu, Yizhi ^a   Liu, Bo ^a   Yang, Yingying ^a   Zhou, Huamei ^a   Wang, Lulu ^a   Wan, Keqiang ^a   Xiao, Xiaoqiu ^b   Zhang, Xia ^a  

^a THE SECOND AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

^b CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Hepatic fibrosis; High fat diet; Insulin resistance; Non alcoholic steatohepatitis; Thiazolidinedione

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADENOSINE MONOPHOSPHATE ACTIVATED PROTEIN KINASE; ADIPONECTIN; ALPHA SMOOTH MUSCLE ACTIN; AMINOTRANSFERASE; COLLAGEN TYPE 1; FATTY ACID; GLUCOSE; INSULIN; MESSENGER RNA; PIOGLITAZONE; PROTEIN KINASE; TRANSFORMING GROWTH FACTOR BETA1; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ACTIVATION; CLINICAL EVALUATION; CONTROLLED STUDY; EXTRACELLULAR MATRIX; FATTY ACID BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HISTOPATHOLOGY; INSULIN BLOOD LEVEL; LIPID DIET; LIVER FIBROSIS; MALE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; STELLATE CELL; TRIACYLGLYCEROL BLOOD LEVEL;

HEPATIC FIBROSIS; HIGH-FAT DIET; INSULIN RESISTANCE; NON-ALCOHOLIC STEATOHEPATITIS; THIAZOLIDINEDIONE;

ANIMALS; BODY WEIGHT; CYCLIC AMP-DEPENDENT PROTEIN KINASES; DIET, HIGH-FAT; FATTY LIVER; HYPOGLYCEMIC AGENTS; LIVER; LIVER CIRRHOSIS; LIVER FUNCTION TESTS; MALE; ORGAN SIZE; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; THIAZOLIDINEDIONES;

EID: 84870286570     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/1440-1681.12020     Document Type: Article

References (40)

1. Caldwell S, Argo C. The natural history of non-alcoholic fatty liver disease. Dig. Dis. 2010; 28: 162-8.
2. Adams LA, Angulo P. Recent concepts in non-alcoholic fatty liver disease. Diabet. Med. 2005; 22: 1129-33.
3. Chitturi S, Farrell GC. Fatty liver now, diabetes and heart attack later? The liver as a barometer of metabolic health. J. Gastroenterol. Hepatol. 2007; 22: 967-9.
4. Polyzos SA, Toulis KA, Goulis DG, Zavos C, Kountouras J. Serum total adiponectin in nonalcoholic fatty liver disease: A systematic review and meta-analysis. Metabolism 2011; 60: 313-26.
5. Ricci R, Bevilacqua F. The potential role of leptin and adiponectin in obesity: A comparative review. Vet. J. 2012; 191: 292-8.
6. Li S, Shin HJ, Ding EL, van Dam RM. Adiponectin levels and risk of type 2 diabetes: A systematic review and meta-analysis. JAMA 2009; 302: 179-88.
7. Tishinsky JM, Robinson LE, Dyck DJ. Insulin-sensitizing properties of adiponectin. Biochimie 2012; 94: 2131-6.
8. Tarqher G, Bertolini L, Rodella S et al. Associations between plasma adiponectin concentrations and liver histology in patients with nonalcoholic fatty liver disease. Clin. Endocrinol. 2006; 64: 679-83.
9. Ma H, Gomez V, Lu L, Yang X, Wu X, Xiao SY. Expression of adiponectin and its receptors in livers of morbidly obese patients with non-alcoholic fatty liver disease. J. Gastroenterol. Hepatol. 2009; 24: 233-7.
10. Yamauchi T, Kamon J, Minokoshi Y et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat. Med. 2002; 8: 1288-95.
11. Handy JA, Saxena NK, Fu P et al. Adiponectin activation of AMPK disrupts leptin-mediated hepatic fibrosis via suppressors of cytokine signaling (SOCS-3). J. Cell. Biochem. 2010; 110: 1195-207.
12. Belfort R, Harrison SA, Brown K et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N. Engl. J. Med. 2006; 355: 2297-307.
13. Ratziu V, Giral P, Jacqueminent S et al. Rosiglitazone for nonalcoholic steatohepatitis: One-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. Gastroenterology 2008; 135: 100-10.
14. Aithal GP, Thomas JA, Kaye PV et al. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology 2008; 135: 1176-84.
15. Da Silva Morais A, Lebrun V, Abarca-Quinones J et al. Prevention of steatohepatitis by pioglitazone: Implication of adiponectin-dependent inhibition of SREBP-1c and inflammation. J. Hepatol. 2009; 50: 489-500.
16. Zib I, Jacob AN, Lingvay I et al. Effect of pioglitazone therapy on myocardial and hepatic steatosis in insulin-treated patients with type 2 diabetes. J. Investig. Med. 2007; 55: 230-6.
17. Gastaldelli A, Miyazaki Y, Mahankali A et al. The effect of pioglitazone on the liver: Role of adiponectin. Diabetes Care 2006; 29: 2275-81.
18. Fan JG, Qiao L. Commonly used animal models of non-alcoholic steatohepatitis. Hepatobiliary Pancreat. Dis. Int. 2009; 8: 233-40.
19. Lee MY, Lee EY, Lee BJ et al. Beneficial effects of thiazolidinediones on diabetic nephropathy in OLETF rats. Yonsei Med. J. 2007; 48: 301-7.
20. Kleiner DE, Brunt EM, Van Natta M et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-21.
21. Ishak K, Baptista A, Bianchi L et al. Histological grading and staging of chronic hepatitis. J. Hepatol. 1995; 22: 696-9.
22. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment. Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-9.
23. Day CP, James OF. Steatohepatitis. A tale of two 'hits'? Gastroenterology 1998; 114: 842-5.
24. Saltiel AR, Olefsky JM. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 1996; 45: 1661-9.
25. Mayerson AB, Hundal RS, Dufour S et al. The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes 2002; 51: 797-802.
26. Cusi K. Role of insulin resistance and lipotoxicity in non-alcoholic steatohepatitis. Clin. Liver Dis. 2009; 13: 545-63.
27. Saha AK, Avilucea PR, Ye JM, Assifi MM, Kraegen EW, Ruderman NB. Pioglitazone treatment activates AMP-activated protein kinase in rat liver and adipose tissue in vivo. Biochem. Biophys. Res. Commun. 2004; 314: 580-5.
28. LeBrasseur NK, Kelly M, Tsao TS et al. Thiazolidinedones can rapidly activate AMP-activated protein kinase in mammalian tissues. Am. J. Physiol. Endocrinol. Metab. 2006; 291: E175-81.
29. Sun K, Wang Q, Huang XH. PPAR gamma inhibits growth of rat hepatic stellate cells and TGF beta-induced connective tissue growth factor expression. Acta Pharmacol. Sin. 2006; 27: 715-23.
30. Ota T, Takamura T, Kurita S et al. Insulin resistance accelerates a dietary rat model of nonalcoholic steatohepatitis. Gastroenterology 2007; 132: 282-93.
31. Wu J, Zern MA. Hepatic stellate cells: A target for the treatment of liver fibrosis. J. Gastroenterol. 2000; 35: 665-72.
32. Watanabe T, Niioka M, Hozawa S et al. Gene expression of interstitial collagenase in both progressive and recovery phase of rat liver fibrosis induced by carbon tetrachloride. J. Hepatol. 2000; 33: 224-35.
33. Ding X, Saxena NK, Lin S, Xu A, Srinivasan S, Anania FA. The roles of leptin and adiponectin: A novel paradigm in adipocytokine regulation of liver fibrosis and stellate cell biology. Am.J. Pathol. 2005; 166: 1655-69.
34. Kamada Y, Tamura S, Kiso S et al. Enhanced carbon tetrachloride-induced liver fibrosis in mice lacking adiponectin. Gastroenterology 2003; 125: 1796-807.
35. Adachi M, Brenner DA. High molecular weight adiponectin inhibits proliferation of hepatic stellate cells via activation of adenosine monophosphate-activated protein kinase. Hepatology 2008; 47: 677-85.
36. Kawaguchi K, Sakaida I, Tsuchiya M, Omori K, Takami T, Okita K. Pioglitazone prevents hepatic steatosis, fibrosis, and enzyme-altered lesions in rat liver cirrhosis induced by a choline-deficient l-amino acid-defined diet. Biochem. Biophys. Res. Commun. 2004; 315: 187-95.
37. Boettcher E, Csako G, Pucino F, Wesley R, Loomba R. Meta-analysis: Pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis. Aliment. Pharmacol. Ther. 2012; 35: 66-75.
38. Wang Z, Xu JP, Zheng YC et al. Peroxisome proliferator-activated receptor gamma inhibits hepatic fibrosis in rats. Hepatobiliary Pancreat. Dis. Int. 2011; 10: 64-71.
39. Scheen A. Glitazones and weight gain. Ann. Endocrinol. 2002; 63: 1S41-4.
40. Ravikumar B, Gerrard J, Dalla Man C et al. Pioglitazone decreases fasting and postprandial endogenous glucose production in proportion to decrease in hepatic triglyceride content. Diabetes 2008; 57: 2288-95.